At the 2026 San Antonio Breast Cancer Symposium®, experts will address evolving treatment strategies for early-stage breast cancers in Clinical Controversies: Disrupting the Paradigm in Early Breast Cancer—Small Tumors Big Choices on Wednesday, December 9, from 1 to 2:15 p.m. CT in Hemisfair Ballroom 1-2 at the Henry B. Gonzalez Convention Center. Kelly Hunt, MD, of The University of Texas MD Anderson Cancer Center, will moderate the session.

Carissia Calvo-Strube, MD, FACS, of The University of Texas at San Antonio, will discuss cryoablation as definitive therapy for early breast cancer.
“Cryoablation was approved by the FDA this past year for the treatment of [certain] small, early-stage, hormone receptor-positive breast cancers in postmenopausal women,” Dr. Hunt said.
Asal Rahimi, MD, of UT Southwestern Medical Center, will explore the current role of stereotactic breast radiation for early breast cancer.
“Typically, we think about radiation as an adjuvant to breast-conserving therapy. However, we are talking about using ablative radiation as a primary treatment of these smaller tumors,” Dr. Hunt said. “It has been shown to be very effective at eradicating such tumors, and often additional treatment is not required.”
Harold Burstein, MD, PhD, of Dana-Farber Cancer Institute, will discuss endocrine therapy as definitive therapy for early, small, hormone receptor–positive breast tumors.
“We are seeing smaller tumors with favorable biology being treated well with endocrine therapy,” Dr. Hunt said.
Medha Deoras-Sutliff, of Ohio State University, will share the patient advocate perspective during a panel discussion.
Session titles, times, and locations are subject to change. For the most up-to-date SABCS 2026 program information, please visit the Program page at SABCS.org.


